Ehrlich Hall

High CV risk populations who may benefit the most from PCSK9i therapy: highlights from the most recent ODYSSEY OUTCOMES data

Evening Session

Ulrich Laufs (Germany)
Ulrich Laufs (Germany)
Dyslipidemia in post-ACS patients: new study results
Helen Colhoun (UK)
Current data on PCSK9i in individuals with diabetes
Klaus Parhofer (Germany)
How to use the armamentarium of novel therapeutic options in high CV risk patients with diabetes
All panellists
Clinical case discussion: clinical implications for managing dyslipidemia in high CV risk populations
Ulrich Laufs (Germany)
Conclusion and key take-away messages
Symposia by: